- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00320892
"Death Rattle" - A Double Blind, Randomly Controlled, Crossover Trial
Dying patients are often unable to clear secretions from their large airways, resulting in noisy breathing usually described as "death rattle." While there is no evidence that patients find this condition disturbing, the noises may be disturbing to the patient's visitors and caregivers who may fear that the patient is choking to death.
In Israel none of the pharmaceutical drugs listed in the literature exist. Thus, Atropine drops which have been noted in the literature as being used, though according to our knowledge no evidence of clinical trials using sublingual Atropine were conducted.
The study is designed as a randomly controlled, double blind crossover trial. The patient will serve as control for himself, as crossover between placebo and drug (randomly chosen) will take place. The administrator of the drug will be blinded to the medication, each time randomly beginning with a different drug (placebo or Atropine).
We will evaluate Atropine Sulphate 1% ophthalmic drops effect on 33 patients using a noise score scale of 0-3. Noise scores will be taken at the start; 30 min after drug/placebo administration and every hour thereafter. After 4-hours crossover will take place and evaluation will follow the same protocol.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Beer-Sheva, Israel, 653
- Ben-Gurion University of the Negev, Sial Research Center for Family Medicine and Primary Care
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- : Patients belonging to Home Palliative Care Unit of Clalit Health Services - Southern District, and the Oncology Department of Soroka University Medical Center and suffering from "death rattle" will be recruited for the study.
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Noise Level
Time Frame: 8 hours
|
30 min after drug administration; and hourly after the initial administration.
if needed a repeat dose will be given and the noise score will be evaluated at 30 min; and hourly thereafter.
The repeat dose will be left to the nurses' discretion if they thought the rattle to be unacceptable.
|
8 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Pesach Shvartzman, Ben-Gurion University of the Negev
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Death
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Adjuvants, Anesthesia
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Pharmaceutical Solutions
- Mydriatics
- Ophthalmic Solutions
- Atropine
Other Study ID Numbers
- SOR416506CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Death
-
University of OxfordRecruitingCause of Mortality | Cause of Neonatal Death | Cause of Child Death | Cause of Maternal Death | Cause of Adult DeathLao People's Democratic Republic, Cambodia, Bangladesh, Myanmar, Thailand
-
Children's Hospital Medical Center, CincinnatiEvery Child Succeeds; de Cavel Family SIDS FoundationCompletedSudden Infant Death Syndrome (SIDS)United States
-
Johns Hopkins UniversityNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingSudden Infant Death | Sudden Unexplained Infant DeathUnited States
-
Johns Hopkins Bloomberg School of Public HealthEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedSudden Infant Death SyndromeUnited States
-
Harvard School of Public Health (HSPH)Population Services International; Community Empowerment LabCompletedPerinatal Death | Stillbirth | Neonatal DeathIndia
-
Nantes University HospitalAXA Assurances VIE MutuelleNot yet recruitingSudden Infant Death | Sudden Unexplained Infant DeathFrance
-
Rachel Moon, MDCompletedSudden Infant Death SyndromeUnited States
-
National Center for Research Resources (NCRR)CompletedSudden Infant Death Syndrome
-
CHU de ReimsCompletedSudden Death in ChildrenFrance
-
Lehigh Valley HospitalCompletedPrevention of Sudden DeathUnited States
Clinical Trials on Atropine Sulphate 1% ophthalmic drops
-
London School of Hygiene and Tropical MedicineCompletedIron-deficiency | Anaemia in Early InfancyGambia
-
Hai Yen Eye CareBrien Holden VisionCompleted
-
Aldeyra Therapeutics, Inc.ORA, Inc.Completed
-
University Eye Hospital, FreiburgRecruiting
-
Aldeyra Therapeutics, Inc.CompletedAllergic Conjunctivitis | Seasonal AllergiesCanada
-
Eye & ENT Hospital of Fudan UniversityShandong Provincial Hospital; Children's Hospital of Fudan University; Xinhua... and other collaboratorsRecruiting
-
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical...Active, not recruiting
-
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical...Active, not recruiting
-
Assiut UniversityCompleted
-
Biomedical Advanced Research and Development AuthorityRho, Inc.CompletedToxic Effect of Organophosphate and Carbamate InsecticidesUnited States